Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.78 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.78 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.78 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.78 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.78 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | BBOX1 | O75936 | 8/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butyric Acid SCHEMBL109152 | 0.92 | FFAR3 (0.82) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL107100 | 0.85 | — | — | |
| Butyric Acid SCHEMBL2587931 | 0.85 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL1176373 | 0.85 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL10908702 | 0.85 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL11441641 | 0.85 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL9800297 | 0.85 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL4292004 | 0.85 | FFAR3 (1.00) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL1330878 | 0.85 | — | — | |
| Butyric Acid SCHEMBL11419652 | 0.85 | FFAR3 (0.93) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9050378-B2 | N2S2 chelate-targeting ligand conjugates | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-06-09 | — | — | US | disclosed |
| CN-103494213-A | Preparation method of fat-burning low-calorie total-nutrient meal replacement preparation | FIRST AFFILIATED HOSPITAL SUN YAT SEN UNIV | 2014-01-08 | — | — | CN | disclosed |
| EP-2316493-A2 | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging | Board of Regents, The University of Texas System (US) | 2011-05-04 | — | — | EP | disclosed |
| US-20050232911-A1 | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid | SCHREIBER BRIAN D | 2005-10-20 | — | — | US | disclosed |
| US-20050129619-A1 | N2S2 chelate-targeting ligand conjugates | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-06-16 | — | — | US | disclosed |
| WO-2004084885-A1 | COMPOSITIONS FOR THE IMPROVEMENT OF OBESITY | AMOREPACIFIC CORPORATION (KR) | 2004-10-07 | — | — | WO | disclosed |
| US-20040166058-A1 | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040166058-A1 | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging | TEK, TIE1, CD40 | FFAR3 1937/4885HDAC3 3581/4885HDAC1 3940/4885 |
| US-20050129619-A1 | N2S2 chelate-targeting ligand conjugates | TYMS, CCNT2, TEK | FFAR3 2121/4885HDAC3 3113/4885HDAC1 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.